Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma

Abstract

Abstract:

AIM: To investigate the relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma. METHODS: 160 surgical specimens of advanced colorectal carcinoma from patients consecutively treated between June 2009 and December 2014 at our hospital were collected. Immunohistochemistry method was used to screen for Syndecan-1 expression. The relationship between Syndecan-1 expression and various clinicopathological parameters, molecular markers, curative effect of FOLFOX was analyzed.RESULTS:Syndecan-1 expression was identified in the cancer cells of 41 (25.6%) colorectal cancer cases, epidermal growth factor receptor expression in 111(69.4%) colorectal cancer cases. The expression of syndecan-1 was statistically correlated with the expression of epidermal growth factor receptor (P<0.05). However, it was not significantly correlated with K-Ras mutation (P>0.05). Patients with over-expressed Syndecan-1 exhibited better efficacy on FOLFOX solution than patients presented negative Syndecan-1 expression (56.1% vs. 40.3%, P<0.05); Patients with over-expressed Syndecan-1 also presented longer median time to progress (8.8 month vs. 7.2 month, P<0.05). CONCLUSION: The expression of Syndecan-1 is referential for evaluating the progress and the prognosis of colorectal cancer. And the expression of Syndecan-1 is statistically correlated with curative effect of FOLFOX regimens.

Key words: colorectal carcinoma, Syndecan-1, EGFR, K-RAS, curative effect of chemotherapy

CLC Number:

R735.3

YUAN Shaofei, ZHU Linjia, ZHENG Weie, LIANG Meizhen. Relationship of Syndecan-1 and EGFR expression, K-Ras gene mutations and response to FOLFOX in advanced colorectal carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 927-932.

References

［1］Teng YH, Aquino RS, Park PW. Molecular functions of Syndecan-1 in disease［J］. Matrix Biol, 2012, 31:3-16.
［2］Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical profiles of Syndecan-1 in solid and hematological cancer for prognosis and precision medicine［J］.Oncotarget, 2015, 6(30):28693-28715.
［3］Pasqualon T, Pruessmeyer J, Weidenfeld S, et al. A transmembrane C-terminal fragment of Syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation［J］.Cell Mol Life Sci, 2015,72(19):3783-3801.
［4］Dobre M, Dinu DE, Panaitescu E, et al. K-Ras gene mutations-prognostic factor in colorectal cancer［J］ ? Rom J Morphol Embryo, 2015, 56(2 Suppl):671-678.
［5］Alves S, Castro L, Fernandes MS.Colorectal cancer-related mutant K-Ras alleles function as positive regulators of autophagy［J］.Oncotarget, 2015, 6(31):30787-30802.
［6］Barresi V, Bonetti LR, Bettelli S. K-Ras, N-Ras, B-RAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases［J］.Pathology, 2015, 47(6):551-556.
［7］Spindler KL, Pallisgaard N, Appelt AL,et al. Clinical utility of K-Ras status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy［J］.Eur J Cancer, 2015, 51(17):2678-2685.
［8］Marino A, Caliolo C, Sponziello F, et al. Panitumumab after progression on cetuximab in K-RAS wild-type metastaticcolorectal cancer patients: a single institution experience［J］.Tumori, 2015,101 (5):524-528.
［9］Kusumoto T, Kodama J, Seki N, et al. Clinical significance of Syndecan-1 and versican expression in human epithelial ovariancancer［J］. Oncol Rep, 2010, 23(9): 917-925.
［10］周霞辉, 吴成就,肖乐东,等.焦磷酸测序技术检测K-RAS基因突变方法的建立［J］.中国临床药理学与治疗学, 2015, 20(4): 430-434.
［11］Lim GH, Tan PH, Jara-Lazaro AR, et al.Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival［J］.Singapore Med J,2014,55(9):468-472.
［12］Xu Y，Yuan J，Zhang Z，et al．Syndeean-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis［J］.Mol Biol Rep, 2012,39(9):8979-8985．
［13］李明武,韩国宏.分子靶向药物治疗晚期胆道肿瘤的研究进展［J］. 临床肝胆病杂志,2014(11):1212-1216.
［14］Phua LC, Ng HW, Yeo AH, et al. Prevalence of K-Ras, B-RAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer［J］.Oncol Lett, 2015, 10(4):2519-2526.
［15］Osumi H, Shinozaki E, Osako M, et al. Cetuximab treatment for metastatic colorectal cancer with K-RAS p.G13D mutations improves progression-free survival［J］.Mol Clin Oncol, 2015, 3(5):1053-1057.
［16］Yazdi MH, Faramarzi MA, Nikfar S, et al. A comprehensive review of clinical trials on EGFR inhibitors such as cetuximab and panitumumab as monotherapy and in combination for treatment of metastatic colorectal cancer［J］.Avicenna J Med Biotechnol, 2015, 7(4):134-144.

[1]	WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei. Mechanism of DCLK1 transcriptional regulation in HCC [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
[2]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[3]	HE Jiaqi, LI Juanjuan, LV Xiaoai, ZHANG Huanhuan, YU Chenhuan. Reversal effects and mechanisms of Flavonoids from Tetrastigma hemsleyanum on drug resistance in gefitinib-resistant lung cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 368-375.
[4]	CHEN Minfang, CHEN Lihua, XIE Liyun, XU Fenfen, XIA Aixiao, LIN Zhong. Preparation and the effect of antitumor of DNA plasmid lipidosome vaccine based VEGFR2 extracellular region by immunization activated in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 24-29.
[5]	SHEN Longde, LI Ailu, LI Lichun, WU Yinyin, SHEN Longyuan, JIANG Qiuxia, HE Jinxi, WU Zhifen, YU Liji, ZHANG Xiaohong. Experimental study on the effect of curcumin on endometriosis in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 862-868.
[6]	BAI Xuemin, ZOU Likao, JIN Zhenmu, JIANG Lijia. Effects of N-acetylcysteine on regulation of EGFR/MAPK signaling pathway in airway mucus hypersecretion in chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1120-1127.
[7]	WANG Lu, ZHENG Xin, WANG Weicong, ZHAO Hongyun, MA Yuxiang, ZHANG Li, HU Pei, JIANG Ji. Pharmacokinetics of the metabolites of abivertinib in Chinese patients with advanced NSCLC in a single and multiple dose group [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1147-1152.
[8]	ZHOU Xia-hui, WU Cheng-jiu, XIAO Le-dong, SUN Li-xian, CAO Zhong. Establishment of pyrosequencing method for detection of k-ras mutation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 430-434.
[9]	WANG Ping, XU Xiao-jing, BU Feng-xiao, ZHOU Yu, YE An, ZHOU Bo-ting. SNP rs1024750 polymorphism in the EGFR gene significantly influences serum calcium levels in postmenopausal Caucasian women [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 772-779.
[10]	WANG Li-ping, WANG Guo, ZHOU Hong-hao. Epidermal growth factor receptor polymorphism development on pharmacodynamics of tyrosine kinase inhibitor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 938-944.
[11]	PAN Pei, WU yan, WANG Rong, WANG Yu-jie, YUAN Yong-fang. Effects of Kanglaite injection on antitumor and expression of EGFR in Lewis lung carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 32-35.
[12]	LUO Hai-yan, HU Chang-lin. Effects of hirudo and earthworm liquor extract on syndecan-1 in rats with experimental cerebral ischemia reperfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(5): 524-527.
[13]	ZHANG Hong-quan, LIU Li. Effects and mechanisms of danshenyin on accelerate gastric ulcer healing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 812-818.
[14]	CAO Qi-Zhen, NIU Gang, GAO Li-Yong, GAO Zi-Fen, TAN Huan-Ran. Detection of gene mutations with PCR and anti-colon cancer monoclonal antibody in tissue and stool of patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 734-738.
[15]	LI Zhe, YUAN Shou-Jun. Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 361-364.